QXO (QXO) had the highest return between October 1, 2023 and January 31, 2024 by a US stock with a market cap of $2B+, returning 302.1%.
| ASSET | DATE | % RETURN |
|---|---|---|
QXO (QXO) | 10/1/2023 - 1/31/2024 | 302.12% |
Edgewise Therapeutics (EWTX) | 10/1/2023 - 1/31/2024 | 211.17% |
Vera Therapeutics (VERA) | 10/1/2023 - 1/31/2024 | 167.01% |
Cytokinetics (CYTK) | 10/1/2023 - 1/31/2024 | 166.11% |
Kymera Therapeutics (KYMR) | 10/1/2023 - 1/31/2024 | 136.68% |
Trump Media & Technology (DJT) | 10/1/2023 - 1/31/2024 | 134.4% |
Oscar Health (OSCR) | 10/1/2023 - 1/31/2024 | 127.64% |
NewAmsterdam Pharma Company NV Ordinary Shares (NAMS) | 10/1/2023 - 1/31/2024 | 126.94% |
Viking Therapeutics (VKTX) | 10/1/2023 - 1/31/2024 | 119.45% |
Summit Therapeutics (SMMT) | 10/1/2023 - 1/31/2024 | 109.63% |
Scholar Rock (SRRK) | 10/1/2023 - 1/31/2024 | 97.87% |
Immunitybio (IBRX) | 10/1/2023 - 1/31/2024 | 97.65% |
Flex (FLEX) | 10/1/2023 - 1/31/2024 | 94.2% |
CleanSpark (CLSK) | 10/1/2023 - 1/31/2024 | 93.21% |
Super Micro Computer (SMCI) | 10/1/2023 - 1/31/2024 | 92.59% |
Rhythm Pharmaceuticals (RYTM) | 10/1/2023 - 1/31/2024 | 92.45% |
TG Therapeutics (TGTX) | 10/1/2023 - 1/31/2024 | 92.19% |
SpringWorks Therapeutics (SWTX) | 10/1/2023 - 1/31/2024 | 91.87% |
Affirm (AFRM) | 10/1/2023 - 1/31/2024 | 91.27% |
Avidity Biosciences (RNA) | 10/1/2023 - 1/31/2024 | 88.44% |
Central Puerto (CEPU) | 10/1/2023 - 1/31/2024 | 84.01% |
Pactiv Evergreen (PTVE) | 10/1/2023 - 1/31/2024 | 81.61% |
Snap (SNAP) | 10/1/2023 - 1/31/2024 | 79.14% |
Gap (GAP) | 10/1/2023 - 1/31/2024 | 79.09% |
Abercrombie & Fitch (ANF) | 10/1/2023 - 1/31/2024 | 78.93% |
